Previous 10 | Next 10 |
2023-03-22 10:02:09 ET Gainers: 89bio ( ETNB ) +38% . SCYNEXIS ( SCYX ) +21% . Athersys ( ATHX ) +20% . Sol-Gel Technologies ( SLGL ) +19% . LifeMD ( LFMD ) +11% . Losers: NuCana ( NCNA ) -10% . Nutex Hea...
2023-03-22 08:13:28 ET Luminar Technologies ( LAZR ) -9% . Petco Health and Wellness ( WOOF ) -9% on Q4 earnings release . Akero Therapeutics ( AKRO ) -8% . Dermata Therapeutics ( DRMA ) -7% . Qualigen Therapeutics ( QLGN ) -7%...
2023-03-21 12:48:20 ET Gainers: U.S. Xpress Enterprises ( USX ) +299% . Dermata Therapeutics ( DRMA ) +81% . First Republic Bank ( FRC ) +40% . Starbox ( STBX ) +36% . BigBear.ai ( BBAI ) +31% . Envirotech Vehicles ( EVTV ...
SAN DIEGO, CA / ACCESSWIRE / March 20, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the closing of its previously announced p...
SAN DIEGO, CA / ACCESSWIRE / March 16, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the pricing of a public offering of 1,618,123 sh...
In a S-1 filing , Dermata Therapeutics ( NASDAQ: DRMA ) announces the launch of of the common stock and warrants in a public offering. Price, size and other terms are not yet determined. The company has engaged H.C. Wainwright to act as its exclusive placement agent in connect...
Dermata Therapeutics press release ( NASDAQ: DRMA ): FY GAAP EPS of -$0.87 beats by $0.03 . Dermata had $6.2 million in cash and cash equivalents, compared to $10.8 million as of December 31, 2021. Dermata expects its current cash resources are sufficient to fund operations in...
- End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 - - Initiation of DMT310 Phase 3 clinical trial program in moderate-to-severe acne patients expected in 2H 2023 - - DMT410 partnering discussions ongoing - SAN DIEGO, CA / ACCESSWIRE / Febru...
3 Tips for Trading Penny Stocks in 2023 Penny stocks, or stocks that trade for less than $5 per share, can be a high-risk, high-reward investment. Because penny stocks are generally not as well known as blue chips, they can be more volatile and may fluctuate significantly in price. Howeve...
3 Ways to Improve Your Chances of Profitability With Penny Stocks Having consistent gains when investing in penny stocks is critical due to the volatile nature of the stock market. The price of penny stocks can fluctuate rapidly and you may end up losing your investment if you are not car...
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Company Name:
DRMA Stock Symbol:
NASDAQ Market:
Dermata Therapeutics Inc. Website:
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...